Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-04-03
2007-04-03
Russel, Jeffrey Edwin (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S012200, C530S324000, C530S326000
Reexamination Certificate
active
10423830
ABSTRACT:
This invention provides novel peptides that ameliorate one or more symptoms of atherosclerosis. The peptides typically range in length up to about 30 amino acids, comprise at least one class A amphipathic helix, and protect a phospholipid against oxidation by an oxidizing agent. The peptides are highly stable and readily administered via an oral route. The peptides are effective to stimulate the formation and cycling of pre-beta high density lipoprotein-like particles and/or to promote lipid transport and detoxification. In addition, the peptides inhibit osteoporosis. When administered with a statin, the peptides enhance the activity of the statin permitting the statin to be used at significantly lower dosages and/or cause the statins to be significantly more anti-inflammatory at any given dose.
REFERENCES:
patent: 3767040 (1973-10-01), Tushaus
patent: 4155913 (1979-05-01), Hellerbach et al.
patent: 4643988 (1987-02-01), Segrest et al.
patent: 4684520 (1987-08-01), Bertelli
patent: 5298490 (1994-03-01), Heavner et al.
patent: 5344822 (1994-09-01), Levine et al.
patent: 5595973 (1997-01-01), Bogden
patent: 5721138 (1998-02-01), Lawn
patent: 5733549 (1998-03-01), Yamada et al.
patent: 5733879 (1998-03-01), Rosseneu et al.
patent: 5814467 (1998-09-01), Curtiss et al.
patent: 5854238 (1998-12-01), Kempen
patent: 6004925 (1999-12-01), Dasseux et al.
patent: 6037323 (2000-03-01), Dasseux et al.
patent: 6046166 (2000-04-01), Dasseux et al.
patent: 6086918 (2000-07-01), Stern et al.
patent: 6265377 (2001-07-01), Dasseux et al.
patent: 6287590 (2001-09-01), Dasseux et al.
patent: 6329341 (2001-12-01), Dasseux et al.
patent: 6376464 (2002-04-01), Dasseux et al.
patent: 6455088 (2002-09-01), Dasseux et al.
patent: 6518412 (2003-02-01), Dasseux et al.
patent: 6573239 (2003-06-01), Dasseux et al.
patent: 6602854 (2003-08-01), Dasseux et al.
patent: 6630450 (2003-10-01), Dasseux et al.
patent: 6664230 (2003-12-01), Fogelman et al.
patent: 6696545 (2004-02-01), Buelow et al.
patent: 6716816 (2004-04-01), Dasseux et al.
patent: 6734169 (2004-05-01), Dasseux et al.
patent: 6753313 (2004-06-01), Dasseux et al.
patent: 2001/0005714 (2001-06-01), Boffelli et al.
patent: 2002/0042441 (2002-04-01), Acton et al.
patent: 2003/0027769 (2003-02-01), Scialdone et al.
patent: 2003/0040505 (2003-02-01), Fogelman et al.
patent: 2003/0045460 (2003-03-01), Fogelman et al.
patent: 2003/0125260 (2003-07-01), Haviv et al.
patent: 185761 (2004-04-01), None
patent: WO 96/41815 (1996-12-01), None
patent: WO 97/36927 (1997-10-01), None
patent: WO 97/36927 (1997-10-01), None
patent: WO 99/16408 (1999-04-01), None
patent: WO 99/47566 (1999-09-01), None
Anantharamaiah (1986) “Synthetic Peptide Analogs of Appolipoproteins.”Methods in Enzymology128:627-647.
Anantharamaiah and Garber (1996) “Chromatographic Methods for Quantitation-of Apolipoprotein A-I.”Meth. Enzymol.263: 267-282.
Anantharamaiah et al. (1985) “Studies of Synthetic Peptide of the Amphipathic Helix.”The Journal of Biological Chemistry260:10248-10255.
Anantharamaiah et al. (1990) “Use of Synthetic Peptide Analogues to Localize Lecithin: Cholseterol Acyltransferase Activating Domain in Apolipoprotein A-I.”Arteriosclerosis10:95-105.
Anantharamaiah et al. (1993) “An Atlas of the Amphipathic Helical Domains of Human Exchangeable Plasma Apolipoproteins.” Chapter. 6:109-142 In:The Amphipathic Helix(Epand, R. M., ed), CRC Press, Boca Raton, FL.
Armstrong et al. (1993) D amino acid levels in human physiological fluids,Chirality, 5: 375-378.
Badimon et al. (1990) “Regression of Atherosclerotic Lesions by High Density Lipoprotein Plasma Fraction in the Cholesterol-fed Rabbit.”J. Clinical Investigation85:1234-1241.
Bauer et al. (1982) “SMS 201-995: A Very Potent and Selective Octapeptide Analogue of Somatostatin with Prolonged Action”Life Sciences31:1133-1140.
Boffelli et al. (1997) “Reconstitution and Further Characterization of the Cholesterol Transport Activity of the Small-Intestinal Brush Border Membrane”Biochemistry36:10784-10792.
Boffelli et al. (1997) “The uptake of cholesterol at the small-intestinal brush border membrane is inhibited by apolipoproteins.” FEBS Letters, 411: 7-11.
Borhani et al. (1999) “Crystal structure of truncated human apolipoprotein A-I suggests a lipid-bound conformation.”Proc. Natl. Acad. Sci. USA. 94:12291-12296.
Brouillette and Anantharamaiah (1995) “Structural models of human apolipoprotein A-I.”Biochim. Biophys. Acta1256: 103-129.
Brouillette et al. (2001) “Structural Models of Human Apolipoprotein A-I: A Critical Analysis and Review”Biochemica et Biophysica Acta55753:1-44.
Canadian Pharmacists Association, Starlix General Monograph. http://cpha.infinetcomm.com/content/hcp/tools/cps—cnp—updates/starlix.cfm, 2002.
Chung et al. (1985) “Studies of Synthetic Peptide Analogs of the Amphipathic Helix.”J. Biol. Chem.60(18): 10256-10262.
Datta et al. (2001) Effects of Increasing Hydrophobicity on the Physical-Chemical and Biological Properties of a Class A Amphipathic Helical Peptide.J Lipid Research42:1096-1104.
Davidson et al. (1994) “The Influence of Apolipoprotein Structure on the Efflux of Celluar Free Cholesterol to High Density Lipoprotein.”J. Biol. Chem.269(37):22975-22982.
Diederich et al. (2001) “Apolipoprotein Al and HDL3Inhibit Spreading of Primary Human Monocytes through a Mechanism that Involves Cholesterol Depletion and Regulation of CD42.”Atherosclerosis159:313-324.
Dooley et al. (1994) “An All D-Amino Acid Opioid Peptide with Central Analgesic Activity from a Combinatorial Library”Science2019-2022.
Dunlop and Neidle (1997) “The Orgion and Turnover of D-Serine in Brain,”Biochemical and Biophysical Research Communication235:26-30.
Ehara et al. (2001) “Elevated Levels of Oxidized Low Density Lipoprotein Show a Positive Relationship With the Severity of Acute Coronary Syndromes.”Circulation103:1955-1960.
Epand et al. (1987) “Studies Synthetic Peptide Analog of the Amphipathic Helix”J. Biol. Chem.262(19):9389-9396.
Field et al. (2001) “Gene expression of sterol regulatory element-binding proteins in hamster small intestine.”Journal of Lipid Research42:1-9.
Fielding and Fielding (1995) “Molescular physiology of reverse cholesterol transport.”J. Lipid Res.36: 211-228.
Fielding et al. (1972) “A Protein of Lecithin: Cholester Acyltransferase.”Biochem. Biophys. Res. Comm.46(2):1493-1498.
Fricker et al. (1995) “Enteral Absorption of Octreotide: Modulation of Intestinal Permeability by Distinct Carbohydrates”The Journal of Pharmacology and Experimental Therapeutics274:826-832.
Fuessl et al. (1987) “Oral Absroption of the Somatostatin Analogue SMS 201-995: Theoretical and Practial Implications”Clinical Science72: 255-257.
Garber et al. (1992) “Turnover of synthetic class A amphipathic peptide analogues of exchangeable apolipoproteins in rats. Correlation with physical properties.”Arteriosclerosis and Thrombosis, 12(8): 886-894.
Garber et al. (1997)Circulation96-I-490.
Garber et al. (1999) “Protection against Atherosclerosis in Mice by a Synthetic Class A Amphipathic Peptide Analog of Apolipoprotein A-I.”Circulation100:2838.
Garber et al. (2001) “A new synthetic class A amphipathic peptide analogue protects mice from diet-induced atherosclerosis.”Journal of Lipid Research42:-545-552.
Glomset (1968) “The Plasma lecithin: cholesterol acytransferase reaction.”J. Lipid Res.9:155-167.
Gong et al. (1994) “Structural and functional properties of human and mouse apolipoprotein A-I.”Biochim. Biophys. Acta1213:335-342.
Gurfinkel et al. (2002) “Influenza Vaccine Pilot Study in Acute Coronary Syndromes and Planned Percutaneous Coronary Interventions. The FLU Vaccination Acute Coronary Syndromes (FLUVACS) Study”Circulation
Anantharamaiah Gattadahalli M
Fogelman Alan M
Navab Mohamad
Beyer & Weaver, LLP
Hunter Tom
Russel Jeffrey Edwin
The Regents of the University of California
LandOfFree
Orally administered peptides synergize statin activity does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Orally administered peptides synergize statin activity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Orally administered peptides synergize statin activity will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3780711